Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ), Pfizer Inc. (PFE): Large Cap Stocks Are Cheaper Than They Appear

Page 1 of 2

Uncertainty creates opportunity for long-term investors, and there is a lot of uncertainty in the healthcare sector right now. As a result, opportunistic investors should take a closer look at companies in this sector.

Companies like Johnson & Johnson (NYSE:JNJ), Merck, and Pfizer Inc. (NYSE:PFE) may be well followed, but, even so, the market sometimes underestimates their earning power. The patent cliff has created enormous uncertainty surrounding these companies’ future revenues, so investors who can reasonably estimate the impact of the patent cliff on their profitability stand to make outsized returns.

Johnson & Johnson (NYSE:JNJ)Compared with the other two companies, Johnson & Johnson (NYSE:JNJ) faces relatively few patent expirations. Moreover, the company’s diverse set of businesses shields it from overexposure to the pharmaceutical industry; in just a few years, Johnson & Johnson’s pharmaceutical segment may represent only one fourth of the company’s total revenue.

The shrinkage of the pharmaceutical segment’s overall contribution has more to do with tailwinds in other segments rather than patent expirations. As the baby boom generation continues to grow older — and live longer — all of Johnson & Johnson (NYSE:JNJ)’s segments should receive a noticeable boost in demand. As a result, the patent cliff is hardly a concern for the company’s long-term earning power.

Pfizer Inc. (NYSE:PFE) and Merck, on the other hand, have suffered greater setbacks as a result of expiring patents, but have new drugs coming down the pipeline. For instance, Singulair, Merck’s single largest revenue source, recently went off patent. However, the company’s new HIV drug and diabetes drug are expected to soften the blow from the loss of Singulair.

Pfizer Inc. (NYSE:PFE), on the other hand, acquired Wyeth in an attempt to shore up its portfolio. The merger is expected to enable the company to earn higher margins, but most of the improvement so far has come through cuts to research and development — which may impact the company’s pipeline.

Investment merits

Johnson & Johnson (NYSE:JNJ) is set to benefit from tremendous tailwinds over the coming decade, while Merck and (NYSE:MRK) Pfizer scramble to replace lost revenue with new drugs. Although the market is aware of these companies’ relative situations, there may still be opportunity in the shares.

On the surface, the price to earnings multiples look unattractive. Johnson & Johnson (NYSE:JNJ) trades at 25 times earnings, Merck at 24 times earnings, and Pfizer Inc. (NYSE:PFE) at 14 times earnings. However, the normalized figures are more attractive. Johnson & Johnson trades at 19 times my estimate of normalized free cash flow, and Merck and Pfizer at 15 times.

Page 1 of 2
Loading Comments...